Cat. No. 4609
Chemical Name: 3,5-Dichloro-2-hydroxy-N-(4-methoxy
Biological ActivityATP citrate lyase (ACL) inhibitor (IC50 = 0.13 μM for human recombinant ACL); blocks lipid synthesis (IC50 = 8 μM in HepG2 cells). Displays no cytotoxicity up to a concentration of 50 μM. Lowers plasma glucose and triglycerides in a mouse model of hyperlipidemia. Orally bioavailable.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Ma et al (2009) A novel direct homogeneous assay for ATP citrate lyase. J.Lipid Res. 50 2131. PMID: 19286649.
Li et al (2007) 2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors. Bioorg.Med.Chem.Lett. 17 3208. PMID: 17383874.
If you know of a relevant reference for BMS 303141 please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses BMS 303141 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: BMS 303141, supplier, BMS303141, ATP, citrate, lyases, inhibits, inhibitors, plasma, glucose, triglycerides, orally, bioavailable, synthases, transferases, ACLY, Tocris Bioscience, ATP Citrate Lyase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent and selective SAM-competitive EZH2 inhibitorBRD 4770
G9a inhibitor and S-adenosyl methionine mimetic; cell permeableLys-CoA
Selective p300 inhibitorUNC 2399
Biotinylated UNC 1999 (Cat.No. 4904)PF 06726304 acetate
Highly potent and SAM-competitive EZH2 inhibitorGSK 591 dihydrochloride
Potent and selective PRMT5 inhibitorTP 064
Potent and selective PRMT 4 inhibitor
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.